Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells

Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells

Abstract Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immun...

Full description

Bibliographic Details
Main Authors: Sisi Chen, Gaoying Chen, Fang Xu, Beibei Sun, Xinyi Chen, Wei Hu, Fei Li, Madiha Zahra Syeda, Haixia Chen, Youqian Wu, Peng Wu, Ruirui Jing, Xinwei Geng, Lingling Zhang, Longguang Tang, Wen Li, Zhihua Chen, Chao Zhang, Jie Sun, Wei Chen, Huahao Shen, Songmin Ying
Format: Article
Language:English
Published: Nature Publishing Group 2022-08-01
Series:Cell Discovery
Online Access:https://doi.org/10.1038/s41421-022-00433-y

Internet

https://doi.org/10.1038/s41421-022-00433-y

Similar Items